Unlocking the opportunity of NAMPT inhibition
Remedy Plan developed a revolutionary medical treatment that targets an essential enzyme—NAMPT—which is critical for healthy cell biology, but becomes dysregulated in dozens of diseases, including cancer. This approach could shift the therapeutic landscape in diseases where essential targets play a key role in disease.
NAMPT: Core regulator of human biology
NAMPT is an essential enzyme that controls how cells use energy, including sugar and fat. NAMPT dysregulation is present in more than 20 diseases, spanning the fields of oncology and autoimmune and metabolic disorders. Its widespread presence is also an opportunity to make a big impact with the right treatment.
The central challenge for therapeutics targeting NAMPT is treating the disease caused by the enzyme's over-activity while also preserving the metabolism of healthy cells. A negative impact on healthy cell activity leads to severe side effects. Successfully targeting NAMPT without the toxic side effects has eluded researchers across the globe, in both academia and some of the biggest pharmaceutical companies.
This all changes with Remedy Plan's
pioneering approach.
Developing the first hyperbolic inhibitors
Remedy Plan is the first team to solve the key challenge of inhibiting NAMPT activity by turning activity down, not off—an approach called hyperbolic inhibition. Our clinical data shows that NAMPT inhibition with our drug, RPT1G, was deemed safe and well-tolerated in a study of healthy adults. This solved NAMPT’s on-target toxicity profile, something that the industry grappled with for decades.
